Grisovin-FP Tablet contains Griseofulvin 250 mg, an antifungal agent primarily used for the treatment of dermatophytic infections of the skin, hair, and nails. Griseofulvin acts by inhibiting fungal cell mitosis through disruption of microtubule function, thereby preventing fungal growth and replication. It is particularly effective against infections caused by Trichophyton, Microsporum, and Epidermophyton species. Grisovin-FP is indicated for conditions such as tinea corporis, tinea cruris, tinea pedis, and onychomycosis. The tablet is administered orally, with absorption enhanced when taken with a fatty meal. Treatment duration varies depending on the site and severity of infection, often requiring several weeks to months for complete resolution. Common adverse effects include headache, gastrointestinal disturbances such as nausea and diarrhea, and photosensitivity reactions. Caution is advised in patients with hepatic impairment or porphyria, and it is contraindicated in pregnancy due to potential teratogenicity. Monitoring liver function tests during prolonged therapy is recommended. Grisovin-FP should be used under medical supervision, ensuring adherence to the prescribed regimen to prevent recurrence and resistance. This medication provides an effective systemic option for managing stubborn dermatophytic infections unresponsive to topical therapy.